Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 100

1.

Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma.

Fasslrinner F, Stölzel F, Kramer M, Teipel R, Brogsitter C, Morgner A, Arndt C, Bachmann M, Hänel M, Röllig C, Kotzerke J, Schetelig J, Bornhäuser M.

Biol Blood Marrow Transplant. 2019 Nov 12. pii: S1083-8791(19)30747-5. doi: 10.1016/j.bbmt.2019.11.007. [Epub ahead of print]

PMID:
31730919
2.

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia.

Röllig C, Kramer M, Schliemann C, Mikesch JH, Steffen B, Krämer A, Sauer T, Hänel M, Herbst R, Schäfer-Eckart K, Noppeney R, Jost E, Brümmendorf TH, Krause SW, Kunzmann V, Einsele H, Scholl S, Hochhaus A, Fransecky LR, Kaufmann M, Neubauer A, Niemann D, Schaich M, Frickhofen N, Kiani A, Heits F, Krümpelmann U, Kaiser U, Kullmer J, Wass M, Klein S, Von Bonin M, Middeke JM, Thiede C, Stoelzel F, Schetelig J, Ehninger G, Baldus CD, Müller-Tidow C, Platzbecker U, Serve H, Bornhäuser M.

Blood. 2019 Nov 13;134(Supplement_1):13. doi: 10.1182/blood-2019-123717.

PMID:
31724019
3.

Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia.

Michallet M, Dreger P, Sobh M, Koster L, Hoek J, Boumendil A, Scheid C, Fox CP, Wulf G, Krüger W, van Gelder M, Corradini P, Russo D, Passweg J, Schoemans H, Bethge W, Schaap N, Cornelissen J, Browne P, Durakovic N, Muller L, Montoto S, Kroger N, Schetelig J; French Cooperative Group for CLL, SFGM-TC, and the EBMT Chronic Malignancy and Lymphoma Working Parties.

Bone Marrow Transplant. 2019 Nov 7. doi: 10.1038/s41409-019-0742-7. [Epub ahead of print]

PMID:
31700137
4.

Frequency of lethal central nervous system neurotoxicity in patients undergoing allogeneic stem cell transplantation: a retrospective registry analysis.

Schultze-Florey CR, Peczynski C, de Marino I, Polge E, Socié G, Blaise D, Beelen D, Franke GN, Kröger N, Stelljes M, Afanasyev B, Potter V, Gerbitz A, Schetelig J, Peric Z, Schoemans H, Koenecke C, Basak GW; EBMT Transplant Complications Working Party (TCWP).

Bone Marrow Transplant. 2019 Nov 6. doi: 10.1038/s41409-019-0738-3. [Epub ahead of print] No abstract available.

PMID:
31695171
5.

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.

Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet EM, Hauptrock B, Dreger P, Luft T, Bethge W, Vogel W, Ciceri F, Peccatori J, Stölzel F, Schetelig J, Junghanß C, Grosse-Thie C, Michallet M, Labussiere-Wallet H, Schaefer-Eckart K, Dressler S, Grigoleit GU, Mielke S, Scheid C, Holtick U, Patriarca F, Medeot M, Rambaldi A, Micò MC, Niederwieser D, Franke GN, Hilgendorf I, Winkelmann NR, Russo D, Socié G, Peffault de Latour R, Holler E, Wolff D, Glass B, Casper J, Wulf G, Menzel H, Basara N, Bieniaszewska M, Stuhler G, Verbeek M, Grass S, Iori AP, Finke J, Benedetti F, Pichlmeier U, Hemmelmann C, Tribanek M, Klein A, Mylius HA, Baumgart J, Dzierzak-Mietla M, Markiewicz M.

Lancet Haematol. 2019 Oct 9. pii: S2352-3026(19)30157-7. doi: 10.1016/S2352-3026(19)30157-7. [Epub ahead of print]

PMID:
31606445
6.

Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas.

Kroschinsky F, Röllig D, Riemer B, Kramer M, Ordemann R, Schetelig J, Bornhäuser M, Ehninger G, Hänel M.

J Cancer Res Clin Oncol. 2019 Dec;145(12):3067-3073. doi: 10.1007/s00432-019-03027-6. Epub 2019 Sep 28.

PMID:
31563974
7.

Clostridium Difficile infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome.

Amberge S, Kramer M, Schröttner P, Heidrich K, Schmelz R, Middeke JM, Gunzer F, Hampe J, Schetelig J, Bornhäuser M, Stölzel F.

Bone Marrow Transplant. 2019 Sep 18. doi: 10.1038/s41409-019-0678-y. [Epub ahead of print]

PMID:
31534193
8.

Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning.

Andersen NS, Bornhäuser M, Gramatzki M, Dreger P, Vitek A, Karas M, Michallet M, Moreno C, van Gelder M, Henseler A, de Wreede LC, Schönland S, Kröger N, Schetelig J; CLL subcommittee, Chronic Malignancies Working Party.

J Cancer Res Clin Oncol. 2019 Nov;145(11):2823-2834. doi: 10.1007/s00432-019-03014-x. Epub 2019 Aug 29.

PMID:
31468122
9.

The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET/CT: final results from the Prospective PETAML Trial.

Stölzel F, Lüer T, Löck S, Parmentier S, Kuithan F, Kramer M, Alakel NS, Sockel K, Taube F, Middeke JM, Schetelig J, Röllig C, Paulus T, Kotzerke J, Ehninger G, Bornhäuser M, Schaich M, Zoephel K.

Haematologica. 2019 Aug 29. pii: haematol.2019.223032. doi: 10.3324/haematol.2019.223032. [Epub ahead of print]

10.

EZH2 mutations and impact on clinical outcome - an analysis in 1604 patients with newly diagnosed acute myeloid leukemia.

Stasik S, Middeke JM, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause S, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Bornhäuser M, Schetelig J, Thiede C.

Haematologica. 2019 Aug 14. pii: haematol.2019.222323. doi: 10.3324/haematol.2019.222323. [Epub ahead of print]

11.

Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation.

Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, Schetelig J, Ganser A, Blaise D, Itälä-Remes M, Passweg JR, Bonifazi F, Finke J, Ruggeri A, Nagler A, Mohty M.

Blood. 2019 Sep 12;134(11):892-899. doi: 10.1182/blood.2019000487. Epub 2019 Jul 3.

PMID:
31270102
12.

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis.

Robin M, de Wreede LC, Wolschke C, Schetelig J, Eikema DJ, Van Lint MT, Knelange NS, Beelen D, Brecht A, Niederwieser D, Vitek A, Bethge W, Arnold R, Finke J, Volin L, Yakoub-Agha I, Nagler A, Poiré X, Einsele H, Chevallier P, Holler E, Ljungman P, Robinson S, Radujkovic A, McLornan D, Chalandon Y, Kröger N.

Haematologica. 2019 Sep;104(9):1782-1788. doi: 10.3324/haematol.2018.205211. Epub 2019 Feb 7.

13.

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.

Schetelig J, de Wreede LC, van Gelder M, Koster L, Finke J, Niederwieser D, Beelen D, Mufti GJ, Platzbecker U, Ganser A, Heidenreich S, Maertens J, Socié G, Brecht A, Stelljes M, Kobbe G, Volin L, Nagler A, Vitek A, Luft T, Ljungman P, Yakoub-Agha I, Robin M, Kröger N.

Leukemia. 2019 Mar;33(3):686-695. doi: 10.1038/s41375-018-0302-y. Epub 2018 Dec 20.

14.

Allele-Level KIR Genotyping of More Than a Million Samples: Workflow, Algorithm, and Observations.

Wagner I, Schefzyk D, Pruschke J, Schöfl G, Schöne B, Gruber N, Lang K, Hofmann J, Gnahm C, Heyn B, Marin WM, Dandekar R, Hollenbach JA, Schetelig J, Pingel J, Norman PJ, Sauter J, Schmidt AH, Lange V.

Front Immunol. 2018 Dec 4;9:2843. doi: 10.3389/fimmu.2018.02843. eCollection 2018.

15.

Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin.

Kuželová K, Brodská B, Schetelig J, Röllig C, Ráčil Z, Walz JS, Helbig G, Fuchs O, Vraná M, Pecherková P, Šálek C, Mayer J.

PLoS One. 2018 Dec 17;13(12):e0204290. doi: 10.1371/journal.pone.0204290. eCollection 2018.

16.

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.

Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlägel U, Mütherig A, Fransecky L, Noppeney R, Bug G, Götze KS, Krämer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stölzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hänel M, Dührsen U, Schetelig J, Röllig C, Kramer M, Ehninger G, Bornhäuser M, Thiede C.

Lancet Oncol. 2018 Dec;19(12):1668-1679. doi: 10.1016/S1470-2045(18)30580-1. Epub 2018 Nov 12.

PMID:
30442503
17.

Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation.

Frick M, Chan W, Arends CM, Hablesreiter R, Halik A, Heuser M, Michonneau D, Blau O, Hoyer K, Christen F, Galan-Sousa J, Noerenberg D, Wais V, Stadler M, Yoshida K, Schetelig J, Schuler E, Thol F, Clappier E, Christopeit M, Ayuk F, Bornhäuser M, Blau IW, Ogawa S, Zemojtel T, Gerbitz A, Wagner EM, Spriewald BM, Schrezenmeier H, Kuchenbauer F, Kobbe G, Wiesneth M, Koldehoff M, Socié G, Kroeger N, Bullinger L, Thiede C, Damm F.

J Clin Oncol. 2019 Feb 10;37(5):375-385. doi: 10.1200/JCO.2018.79.2184. Epub 2018 Nov 7.

PMID:
30403573
18.

T-cell receptor-α repertoire of CD8+ T cells following allogeneic stem cell transplantation using next-generation sequencing.

Link-Rachner CS, Eugster A, Rücker-Braun E, Heidenreich F, Oelschlägel U, Dahl A, Klesse C, Kuhn M, Middeke JM, Bornhäuser M, Bonifacio E, Schetelig J.

Haematologica. 2019 Mar;104(3):622-631. doi: 10.3324/haematol.2018.199802. Epub 2018 Sep 27.

19.
20.

Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation.

Chitre S, Stölzel F, Cuthill K, Streetly M, Graham C, Dill C, Mohamedali A, Smith A, Schetelig J, Altmann H, Bornhäuser M, Mufti GJ.

Leukemia. 2018 Sep;32(9):2020-2024. doi: 10.1038/s41375-018-0208-8. Epub 2018 Jul 19. No abstract available.

PMID:
30026569

Supplemental Content

Loading ...
Support Center